Becton, Dickinson and Company (BDX) is set to release its fiscal 3Q16 earnings results on August 4, 2016.
In a Bloomberg survey of 19 brokerage companies taken on July 26, 2016, about 58% of analysts rated BDX as a “buy,” and 42% rated it as a “hold.” No analysts rated BDX as a “sell.”
The table above lists the 13 brokerage companies that have provided target prices for BDX for the next 12 months. The consensus 12-month target price for BDX is $182.5, amounting to a return potential of ~5.6% over BDX’s price of $172.8 on July 25, 2016.
On July 26, RBC Capital Markets gave BDX a one-year target price of $169, the company’s lowest target price. This target implies a -2.2% return over the next 12 months.
Among large investment banks, JPMorgan Chase gave BDX a one-year target price of $178, implying a ~3% return potential over the next 12 months. Raymond James gave BDX a one-year target price of $200, implying a ~15.7% return potential over the next 12 months.
Peers Boston Scientific (BSX), Medtronic (MDT), and Baxter International (BAX) have average broker target prices of $25.2, $92.9, and $48.9, respectively. These figures imply returns of 6.1%, 7%, and 6.1%, respectively, over the next 12 months.
ETFs with exposures to BDX
Investors can get exposure to BDX by investing in the PowerShares Dynamic Market ETF (PWC), which has 2.4% of its total holdings in BDX.
The SPDR S&P Dividend ETF (SDY) has ~0.69% of its total holdings in BDX. Investors can also gain exposure to BDX through the iShares U.S. Medical Devices ETF (IHI), which has 5.4% of its total holdings in BDX.